AVPR2 and autosomal dominant polycystic kidney disease: As of today, the selective vasopressin V2 receptor antagonist tolvaptan (Jinarc® (EU, UK, Canada), Jynarque® (USA), Samsca® (Japan)) is the only available treatment that can slow cyst growth in ADPKD patients [10,11].